Signalling a new era in cancer care, this week the US Food and Drug Administration approved the first treatment that genetically engineers patients’ own blood cells.
Keeping up with what’s going on in the industry can be a bit of a headache; there are new studies coming out every day and new initiatives launching all the time.
Transform your clinical trials with Archer’s unparalleled accuracy and efficiency
visit our website, request a demo, or contact us at sales@ignitedata.com to learn more.
